[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Lupattelli M, Mascioni F, Bellavita R, Draghini L, Tarducci R, Castagnoli P, Russo G, Aristei C: Long-term anorectal function after postoperative chemoradiotherapy in high-risk rectal cancer patients. Tumori; 2010 Jan-Feb;96(1):34-41
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term anorectal function after postoperative chemoradiotherapy in high-risk rectal cancer patients.
  • AIMS AND BACKGROUND: After sphincter-preserving surgery for rectal cancer and postoperative radiochemotherapy, many patients have unsatisfactory anorectal functional results which are not considered by the most common toxicity scales.
  • The aim of the present study was to retrospectively assess the long-term incidence of impaired anorectal function in rectal cancer patients who underwent anterior resection and postoperative radiochemotherapy.
  • METHODS: Ninety-nine patients who underwent sphincter-saving surgery and postoperative radiochemotherapy for stage II-III rectal cancer from July 1991 to January 2002 were given a questionnaire on anorectal function.
  • [MeSH-major] Anal Canal / physiopathology. Rectal Neoplasms / therapy. Rectum / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20437855.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


2. Vini L: Neoadjuvant radiochemotherapy for rectal cancer. Dig Dis; 2007;25(1):56-66
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant radiochemotherapy for rectal cancer.
  • During the past few decades, significant progress has been achieved in the management of rectal cancer with the introduction of total mesorectal excision.
  • Several recent studies show that 5-FU-based chemotherapy enhances tumor response to radiotherapy and preoperative chemoradiotherapy is being increasingly used for stage II and III disease.
  • [MeSH-minor] Anal Canal. Combined Modality Therapy. Humans. Preoperative Care. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 S. Karger AG, Basel.
  • (PMID = 17384509.001).
  • [ISSN] 0257-2753
  • [Journal-full-title] Digestive diseases (Basel, Switzerland)
  • [ISO-abbreviation] Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


3. Katsui R, Kuniyasu H, Matsuyoshi H, Fujii H, Nakajima Y, Takaki M: The plasticity of the defecation reflex pathway in the enteric nervous system of guinea pigs. J Smooth Muscle Res; 2009 Feb;45(1):1-13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Appropriate rectal distension elicits rectal (R-R) reflex contractions and simultaneous internal anal sphincter (R-IAS) reflex relaxations that together comprise the defecation reflex.
  • We performed either a lower anterior resection as used for rectal cancer, without damaging the extrinsic nerves or a resection of a 2-cm segment of distal colon, 30 mm orally from the anal verge, with subsequent end-to-end one layer anastomosis of the exposed ends.
  • The 5-HT(4) receptor agonist, mosapride (0.5 and 1.0 mg/kg), significantly (P<0.01) enhanced the recovered defecation reflex at this stage.
  • Two weeks after local treatment with brain-derived neurotrophic factor (BDNF: 10(-6) g/ml) at the rectal anastomotic site, the R-IAS reflex relaxations recovered and some bundles of fine nerve fibers were able to be seen interconnecting the oral and anal ends of the myenteric plexus.
  • [MeSH-major] Anal Canal / innervation. Benzamides / pharmacology. Brain-Derived Neurotrophic Factor / pharmacology. Colon / innervation. Morpholines / pharmacology. Neuronal Plasticity. Serotonin Receptor Agonists / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19377268.001).
  • [ISSN] 1884-8796
  • [Journal-full-title] Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi
  • [ISO-abbreviation] J Smooth Muscle Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Benzamides; 0 / Brain-Derived Neurotrophic Factor; 0 / Morpholines; 0 / Serotonin Receptor Agonists; I8MFJ1C0BY / mosapride
  • [Number-of-references] 28
  •  go-up   go-down


Advertisement
4. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, Halverson AL: Squamous cell carcinoma of the anal canal: utilization and outcomes of recommended treatment in the United States. Ann Surg Oncol; 2008 Jul;15(7):1948-58
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the anal canal: utilization and outcomes of recommended treatment in the United States.
  • BACKGROUND: Over the past two decades, recommended treatment for squamous cell carcinoma of the anal canal has shifted from surgery to primary chemoradiation.
  • METHODS: From the National Cancer Data Base (1985-2005), 38,882 patients with anal canal cancer were identified.
  • Patients were significantly less likely to receive guideline treatment if male, older, black or Hispanic, more severe comorbidities, or Stage I (vs Stage II or III).
  • [MeSH-major] Anus Neoplasms / therapy. Neoplasms, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18414951.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


5. Gavioli M, Losi L, Luppi G, Iacchetta F, Zironi S, Bertolini F, Falchi AM, Bertoni F, Natalini G: Preoperative therapy for lower rectal cancer and modifications in distance from anal sphincter. Int J Radiat Oncol Biol Phys; 2007 Oct 1;69(2):370-5
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative therapy for lower rectal cancer and modifications in distance from anal sphincter.
  • PURPOSE: To assess the frequency and magnitude of changes in lower rectal cancer resulting from preoperative therapy and its impact on sphincter-saving surgery.
  • Preoperative therapy can increase the rate of preserving surgery by shrinking the tumor and enhancing its distance from the anal sphincter.
  • METHODS AND MATERIALS: A total of 98 cases of locally advanced cancer of the lower rectum (90 Stage uT3-T4N0-N+ and 8 uT2N+M0) that had undergone preoperative therapy were studied by endorectal ultrasonography.
  • The maximal size of the tumor and its distance from the anal sphincter were measured in millimeters before and after preoperative therapy.
  • The distance between the tumor and the anal sphincter increased in 60.2% of cases.
  • It was possible in nearly 30% of patients in whom the cancer had reached the anal sphincter before the preoperative therapy.
  • CONCLUSION: The results of our study have shown that in very low rectal cancer, preoperative therapy causes tumor downsizing in >80% of cases and in more than one-half enhances the distance between the tumor and anal sphincter.
  • [MeSH-major] Anal Canal / pathology. Rectal Neoplasms / pathology. Rectal Neoplasms / therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17524570.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


6. Bilimoria KY, Bentrem DJ, Rock CE, Stewart AK, Ko CY, Halverson A: Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Dis Colon Rectum; 2009 Apr;52(4):624-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base.
  • PURPOSE: The objective of this study was to assess survival and prognostic factors for anal carcinoma in the population.
  • METHODS: Patients with squamous-cell carcinoma of the anal canal were identified from the National Cancer Data Base (1985-2000).
  • Concordance was calculated to assess agreement between American Joint Committee on Cancer stage and actual outcome.
  • RESULTS: Nineteen thousand one hundred ninety-nine patients with anal carcinoma were identified (Stage I, 25.3 percent; Stage II, 51.8 percent; Stage III, 17.1 percent; Stage IV, 5.7 percent).
  • The American Joint Committee on Cancer (6th edition) staging system provided good survival discrimination by stage: I, 69.5 percent; II, 59.0 percent; III, 40.6 percent; and IV, 18.7 percent (concordance index, 0.663).
  • On multivariable analysis, patients with anal carcinoma had a higher risk of death if they were male, >or=65 years old, black, living in lower median incomes areas, and had more advanced T stage tumors, nodal or distant metastases, or poorly differentiated cancers (P < 0.0001).
  • CONCLUSION: Although tumor characteristics and staging affect prognosis, patient factors, such as gender, race, and socioeconomic status, are also important prognostic factors for squamous-cell carcinoma of the anal canal.
  • [MeSH-major] Anus Neoplasms / mortality. Carcinoma, Squamous Cell / mortality

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404066.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


7. Tournier-Rangeard L, Peiffert D, Lafond C, Mege A, Metayer Y, Marchesi V, Buchheit I, Uwer L, Conroy T, Kaminsky MC: [Long-term results and prognostic factors of squamous cell carcinoma of the anal canal treated by irradiation]. Cancer Radiother; 2007 Jun;11(4):169-77
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term results and prognostic factors of squamous cell carcinoma of the anal canal treated by irradiation].
  • [Transliterated title] Résultats à long terme et facteurs pronostiques des carcinomes épidermoïdes du canal anal traités par irradiation.
  • PURPOSE: To analyze the prognostic factors of loco regional control (LRC), specific survival (SS) and sphincter conservation (SC) of patients treated by curative and conservative irradiation for an epidermoid cancer of anal canal in our institution.
  • Forty-three pts were stage I, 154 stage II, 31 stage IIIA and 53 stage IIIB.
  • Five-years-LRC were 71.5% (88% for stage I, 69% for stage II, 77%, for stage IIIA and 60% for stage IIIB).
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17400501.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


8. Roohipour R, Patil S, Goodman KA, Minsky BD, Wong WD, Guillem JG, Paty PB, Weiser MR, Neuman HB, Shia J, Schrag D, Temple LK: Squamous-cell carcinoma of the anal canal: predictors of treatment outcome. Dis Colon Rectum; 2008 Feb;51(2):147-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous-cell carcinoma of the anal canal: predictors of treatment outcome.
  • PURPOSE: The incidence of anal canal squamous-cell carcinoma is increasing.
  • METHODS: Using one database, we identified 131 Stages I-III patients treated for primary anal canal squamous-cell carcinoma at our institution from December 1986 to August 2006, with minimum six-month follow-up.
  • RESULTS: Of 131 patients (median age, 58.3 years; median follow-up, 2.9 (range, 0.6-11.2) years), 66 percent were females, 43.5 percent were Stage II, and 11 (8 percent) were HIV-positive.
  • Almost all patients undergoing radiotherapy (96.7 percent, 118/122) also had chemotherapy: 118 (100 percent, Stages I-III) had concurrent chemotherapy: (98 (83.8 percent) mitomycin/5-fluorouracil, 12 (10.2 percent) cisplatin/5-fluorouracil, 8 (6.8 percent) 5-fluorouracil alone); 35 of 46 (76 percent) Stage III patients received induction chemotherapy (34 (97.1 percent) cisplatin/5-fluorouracil, 1 (2.8 percent) 5-fluorouracil alone).
  • Many (44 percent Stages I/II, 48.9 percent Stage III) required dose adjustments.
  • Bivariate analyses demonstrated that T stage (P=0.0019), completion of radiotherapy, and total radiotherapy dose (P=0.03) were all significantly associated with treatment failure.
  • On multivariate analyses, disease stage (P=0.05) and completion of radiotherapy (P=0.01) remained significant predictors of relapse-free survival.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Dis Colon Rectum. 2008 May;51(5):620
  • (PMID = 18180997.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


9. Tajima Y, Ishibashi K, Gonda T, Miyazaki T, Nakada H, Takahashi T, Ishida H: [Squamous cell carcinoma of the anal canal showing complete response following chemoradiotherapy--a case report]. Gan To Kagaku Ryoho; 2007 Nov;34(12):2050-2
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Squamous cell carcinoma of the anal canal showing complete response following chemoradiotherapy--a case report].
  • We report a case of squamous cell carcinoma of the anal canal which showed complete response following chemoradiotherapy.
  • A 54-year-old woman was diagnosed as having squamous cell carcinoma of the anal canal (T2N0M0 stage II).
  • This case suggests that we should take measures to prevent distant metastases in the treatment of squamous cell carcinoma of the anal canal.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18219895.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


10. Ferrigno R, Nakamura RA, Dos Santos Novaes PE, Pellizzon AC, Maia MA, Fogarolli RC, Salvajoli JV, Filho WJ, Lopes A: Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness. Int J Radiat Oncol Biol Phys; 2005 Mar 15;61(4):1136-42
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness.
  • PURPOSE: This retrospective analysis reports the results on patients with anal canal carcinoma treated by combined radiotherapy and chemotherapy.
  • METHODS AND MATERIALS: Between March 1993 and December 2001, 43 patients with anal canal carcinoma were treated with radiochemotherapy at the Hospital do Cancer A.C. Camargo.
  • Stage distribution was as follows: I, 3 (7%); II, 23 (53.5%); IIIA, 8 (18.6%); and IIIB, 9 (21%).
  • Patient's age, tumor stage, overall treatment time, and RT dose at primary tumor were variables analyzed for survival and local control.
  • Overall survival according to clinical stage was as follows: I, 100%; II, 82%; IIIA, 73%; and IIIB, 18% (p = 0.0049).
  • CONCLUSIONS: This analysis suggests that the treatment scheme employed was effective for anal sphincter preservation and local control; however, the incidence of distant metastases was relatively high.
  • The clinical stage was the main prognostic factor for overall survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15752894.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Widder J, Kastenberger R, Fercher E, Schmid R, Langendijk JA, Dobrowsky W, Pötter R: Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients. Radiother Oncol; 2008 Jun;87(3):367-75
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients.
  • BACKGROUND AND PURPOSE: To retrospectively analyse a large consecutive cohort of patients with anal cancer for treatment-related factors influencing local control and survival.
  • MATERIALS AND METHODS: All patients referred for primary radiotherapy at Medical University of Vienna in 1990-2002 with anal canal carcinoma without distant metastases were analysed.
  • RESULTS: Median age was 67 years (n=129), the UICC stage distribution was 15%, 58%, and 27% for stages I, II, and III, respectively.
  • Stage and age were significant factors for overall and colostomy-free-survival, N-stage for disease-free-survival.
  • Shorter overall treatment time favoured local control in stage T1-2 (p=.015), higher total radiation dose and female gender were associated with improved local control in T3-4 tumours (p=.021).
  • CONCLUSIONS: These results support potential improvement of anal cancer treatment by studying advanced technology such as IMRT, making it possible to tailor high-dose regions.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18501453.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


12. Selvindos PB, Ho YH: Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis. Dis Colon Rectum; 2008 Nov;51(11):1710-1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis.
  • PURPOSE: Optimal treatment of mid to distal rectal cancers includes total mesorectal excision for oncologic clearance and, where reanastomosis is feasible, a colonic J-pouch-anal anastomosis improves bowel function.
  • Bowel continuity was restored by an intracoporeal double-cross stapled colonic J-pouch-anal anastomosis, but where not possible a coloplasty with pull-through handsewn coloanal anastomosis was performed.
  • The indications were adenocarcinoma (n = 51), squamous-cell carcinoma of rectum (n = 1), dermoid tumor of mesorectum (n = 1), large villous adenoma (n = 1), and carcinoid with local lymph node metastases (n = 1).
  • The adenocarcinomas were a median distance of 6 (3-12) cm from the anal verge.
  • The histologic grading or the adenocarcinoma patients were: Stage I, n = 14; Stage II, n = 23; Stage III, n = 11; Stage IV, n = 3.
  • The level of the coloanal anastomosis was a median 3.5 (0-4.5) cm from the anal verge; a coloanal pull-through anastomosis was required in one patient who had a distal cancer.
  • Four other patients had smaller pelvic collections that resolved with antibiotics; pelvic collections were associated with advanced stage of cancer (P = 0.047).
  • This brought the rectum proximally and anteriorly, aiding with the laparoscopic stapler transection of the distal rectum, especially if the cancer was distal, the patient was obese, and the pelvis was narrow.
  • Further randomized, controlled studies that include assessing five-year cancer survival/recurrence, pelvic nerve dysfunction, and bowel function are needed before laparoscopic ultralow anterior resection becomes widely accepted.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Colonic Pouches. Laparoscopy / methods. Proctocolectomy, Restorative / methods. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18679748.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Interactive Tutorial
  • [Publication-country] United States
  •  go-up   go-down


13. Hamada M, Ozaki K, Iwata J, Nishioka Y, Horimi T: A case of rectosigmoid cancer metastasizing to a fistula in ano. Jpn J Clin Oncol; 2005 Nov;35(11):676-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of rectosigmoid cancer metastasizing to a fistula in ano.
  • We herein report a case of rectosigmoid cancer metastasizing to a fistula in ano.
  • A 53-year-old man complaining of anal bleeding consulted another hospital.
  • He had been suffering from an anal fistula since 7 years.
  • On the left upper side of the skin surface around the anus a fistula end was seen as a hole that tunneled down into the back passage, although no hard tumor was palpable on the hole.
  • The post-operative pathological diagnosis was rectosigmoid cancer, Type 2, T2, N0, M0, stage II.
  • The anal fistula was a simple type and mucinous discharge was not observed.
  • On 23 February 2004, coring out the anal fistula was performed by the former hospital.
  • We diagnosed this tumor as metastatic adenocarcinoma from a rectosigmoid cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Anus Neoplasms / secondary. Rectal Fistula / pathology. Rectal Neoplasms / pathology. Sigmoid Neoplasms / pathology
  • [MeSH-minor] Anal Canal / pathology. Humans. Lymph Node Excision. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16275674.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Eng C, Chang GJ, Das P, Rodriguez-Bigas M, Skibber JM, Qiao W, Rosner GL, Ukegbu LT, Wolff RA, Crane CH: Phase II study of capecitabine and oxaliplatin with concurrent radiation therapy (XELOX-XRT) for squamous cell carcinoma of the anal canal. J Clin Oncol; 2009 May 20;27(15_suppl):4116

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of capecitabine and oxaliplatin with concurrent radiation therapy (XELOX-XRT) for squamous cell carcinoma of the anal canal.
  • : 4116 Background: Definitive therapy for squamous cell carcinoma (SCC) of the anal canal consists of external beam radiotherapy with concurrent 5-fluorouracil and mitomycin C or cisplatin.
  • The purpose of this study was to evaluate the tolerability and efficacy of XELOX-XRT as definitive treatment for anal cancer.
  • METHODS: Patients with histologically proven SCC of the anal canal, AJCC Stage II-IIIB (T<sub>2-4</sub> or N+M<sub>0</sub>), ECOG PS 0-1, HIV<sup>-</sup>, and no prior therapy were eligible for XELOX-based chemoradiotherapy.
  • CONCLUSIONS: The combination of capecitabine, oxaliplatin, and radiation therapy (XELOX-XRT) is effective for locally advanced squamous cell carcinoma of the anal canal.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961220.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Swampillai A, Williams M, Osborne M, Mawdsley S, Hughes R, Harrison M, Glynne-Jones R: A single-center study of the utility of squamous cell carcinoma antigen (SCCAg) levels in epidermoid carcinoma of the anal canal and margin (ECACM) treated with chemoradiation (CRT). J Clin Oncol; 2009 May 20;27(15_suppl):4117

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single-center study of the utility of squamous cell carcinoma antigen (SCCAg) levels in epidermoid carcinoma of the anal canal and margin (ECACM) treated with chemoradiation (CRT).
  • Radiotherapy comprised the schedule of the UK Anal cancer Trial (ACT II).
  • Clinical stage at diagnosis- Tx (6) T1 (28), T2 (80), T3 (65), T4 (16), N0 (126), N+ (66) Nx (3).
  • RESULTS: Mean baseline SCCAg by cT and cN stage were: T1 93 (ng/dl), T2 300, T3 607, T4 882, N0 376, N+ 529 (correlation coeff: T: 0.47, N: 0.33, both p< 0.001).
  • CONCLUSIONS: There is a correlation between T and N stage and baseline SCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961219.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Wang JP, Wu XJ, Song XM, Wang L, Huang MJ, Lan P: [Changes of sphincter preserving rate in lower rectal cancer and analysis of their related factors]. Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Mar;9(2):107-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Changes of sphincter preserving rate in lower rectal cancer and analysis of their related factors].
  • OBJECTIVE: To analyze the factors related to sphincter preserving(SP) operation for lower rectal cancer.
  • METHODS: Clinicopathological data of 316 patients with lower rectal cancer 1-5 cm from the anorectal line who underwent surgical resection from Aug.
  • 1998) to 76.2 % in period II (Jan. 1999-Nov. 2005)(P=0.000).
  • Significant differences were detected between the two period in sex, volume of blood transfusion, Dukes' stage (P< 0.05).
  • [MeSH-major] Anal Canal / surgery. Rectal Neoplasms / surgery. Rectum / surgery

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16555145.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


17. Li SY, Liang ZJ, Yuan SJ, Yu B, Chen G, Zuo FY, Bai X, Chen G, Wei XJ, Xu YS, Cui W: [Clinical experience of 371 cases of sphincter-preservation with telescopic anastomosis after radical excision for low-middle rectal cancer]. Zhonghua Wei Chang Wai Ke Za Zhi; 2010 Apr;13(4):263-5
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical experience of 371 cases of sphincter-preservation with telescopic anastomosis after radical excision for low-middle rectal cancer].
  • OBJECTIVE: To evaluate the clinical efficacy, feasibility and safety of sphincter-preservation with telescopic anastomosis of colon and rectal mucosa in low-middle rectal cancer.
  • METHODS: A retrospective analysis was carried out in 371 patients with low-middle rectal cancer in whom telescopic anastomosis was used.
  • The lower margins of the tumors located between 5-8 cm from the anal verge.
  • According to the Duke's stage classification, 120 were TNM stage I, 222 stage II, 26 stage III, and 3 stage IV.
  • CONCLUSION: The sphincter-preservation with telescopic anastomosis procedure is safe and effective for low-middle rectal cancer, and the sphincter function can be well-preserved.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Anastomosis, Surgical / methods. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20422480.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


18. Wu XJ, Wang JP, Wang L, He XS, Zou YF, Lian L, Zhang LJ, Lan P: Increased rate change over time of a sphincter-saving procedure for lower rectal cancer. Chin Med J (Engl); 2008 Apr 5;121(7):636-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased rate change over time of a sphincter-saving procedure for lower rectal cancer.
  • BACKGROUND: Total mesorectal excision (TME) has increased the rate of sphincter-preservation (SP) for more patients with low-lying rectal cancer.
  • Here, we analyze the change of sphincter preserving rates in lower rectal cancer and their related factors.
  • The 12-year span was divided into 2 periods: period I (August 1994-December 1998) and period II (January 1999-November 2005), based on the date (January 1999) when standard total mesorectal excision (TME) was introduced.
  • RESULTS: The SP rate increased significantly over the 12 years, from 44.9% in period I to 76.2% in period II (P = 0.000).
  • Significant differences were detected between the two time periods in gender, blood transfusion volume and Dukes' stage (P < 0.05).
  • The leakage rate was 2.7% in period I and 1.3% in period II (P > 0.05).
  • [MeSH-minor] Adult. Aged. Anal Canal / surgery. Anastomosis, Surgical. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18466685.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


19. Gervaz P, Lavertu S, Kazemba B, Pemberton JH, Haddock MG, Gunderson LL: Sphincter-preserving radiation therapy for rectal cancer: a simulation study using three-dimensional computerized technology. Colorectal Dis; 2006 Sep;8(7):570-4
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sphincter-preserving radiation therapy for rectal cancer: a simulation study using three-dimensional computerized technology.
  • This approach provides, in theory, a means to selectively subtract the anal sphincter from the high-dose field of irradiation in patients with stage II and III adenocarcinomas of the mid-rectum scheduled for low anterior resection (LAR).
  • HYPOTHESIS: Implementation of 3DXRT with sphincter blocking may be a feasible strategy to reduce the dose of radiation distributed to the anal canal without reduction in the dose distribution to the gross tumour volume (GTV) plus adequate margins.
  • METHODS: Pretreatment simulation CT scans of 10 patients with rectal cancers located between 5 and 10 cm from the anal verge were retrieved from a computerized database.
  • Radiation oncologists and colorectal surgeons defined the contours of the GTV and the anal sphincter, respectively, on successive CT scan slices.
  • RESULTS: The mean distance of tumours from the anal verge was 6.3 cm.
  • The mean volume of the anal sphincter was 16.1 +/- 3.5 cm(3).
  • By comparison the mean dose distributed to the anal sphincter was dramatically reduced by using a sphincter block (33.2 +/- 12 Gy vs 6.4 +/- 4.1 Gy, P < 0.001).
  • CONCLUSION: During a course of radiotherapy for most low- or mid-rectal cancers, the anal canal is included within the field of irradiation with a mean dose distribution to the sphincter of 33 Gy.
  • Evaluation of 3DXRT with full sphincter block (mid-rectum) and partial sphincter block (distal rectum) is a feasible strategy to decrease the volume of anal sphincter carried to full dose without reduction in dose to the GTV.
  • This approach, by minimizing treatment-induced damage to the anal sphincter, might improve functional outcome of LAR.
  • [MeSH-major] Anal Canal / radiation effects. Computer Simulation. Radiotherapy Planning, Computer-Assisted. Rectal Neoplasms / radiotherapy. Rectal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16919108.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


20. Weiser MR, Quah HM, Shia J, Guillem JG, Paty PB, Temple LK, Goodman KA, Minsky BD, Wong WD: Sphincter preservation in low rectal cancer is facilitated by preoperative chemoradiation and intersphincteric dissection. Ann Surg; 2009 Feb;249(2):236-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sphincter preservation in low rectal cancer is facilitated by preoperative chemoradiation and intersphincteric dissection.
  • OBJECTIVE: The aim of this study was to evaluate oncologic outcome in patients with locally advanced distal rectal cancer treated with preoperative chemoradiation followed by low anterior resection (LAR)/stapled coloanal anastomosis, LAR/intersphincteric dissection/hand-sewn coloanal anastomosis, or abdominoperineal resection (APR).
  • SUMMARY BACKGROUND DATA: Distal rectal cancer presents a surgical challenge, and the goals of treatment often include tumor eradication without sacrifice of the anal sphincters.
  • The technique of intersphincteric resection removes the internal anal sphincter to gain additional distal rectal margin in hopes of avoiding a permanent stoma.
  • METHODS: We analyzed 148 patients with stage II and III rectal cancers (endorectal ultrasound staged uT3-4 and/or uN1) located < or =6 cm from the anal verge, treated by preoperative chemoradiation and total mesorectal excision from 1998 to 2004.
  • CONCLUSIONS: In low rectal cancer, sphincter preservation is facilitated by a significant response to preoperative chemoradiation and intersphincteric resection, without compromise of margins or outcome.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / physiopathology. Anal Canal / surgery. Antineoplastic Agents / administration & dosage. Colectomy. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212176.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


21. Garlipp B, Ptok H, Schmidt U, Meyer F, Gastinger I, Lippert H: Neoadjuvant chemoradiotherapy for rectal carcinoma: effects on anastomotic leak rate and postoperative bladder dysfunction after non-emergency sphincter-preserving anterior rectal resection. Results of the Quality Assurance in Rectal Cancer Surgery multicenter observational trial. Langenbecks Arch Surg; 2010 Nov;395(8):1031-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemoradiotherapy for rectal carcinoma: effects on anastomotic leak rate and postoperative bladder dysfunction after non-emergency sphincter-preserving anterior rectal resection. Results of the Quality Assurance in Rectal Cancer Surgery multicenter observational trial.
  • INTRODUCTION: Randomized trials have demonstrated a reduction in local recurrence rate in rectal cancer patients treated with preoperative chemoradiotherapy and total mesorectal excision (TME) compared to patients undergoing TME alone.
  • Accordingly, preoperative chemoradiotherapy in all UICC stages II and III rectal cancers has been recommended in the German treatment guidelines as of 2004.
  • It was the aim of our analysis to investigate the influence of preoperative chemoradiotherapy on anastomotic leak rate and postoperative bladder dysfunction in rectal cancer patients using a representative data set from the Quality Assurance in Rectal Cancer Surgery multicenter observational trial.
  • METHOD: This is a retrospective analysis of data from the Quality Assurance in Rectal Cancer Surgery prospective multicenter observational trial.
  • Data of all patients undergoing curatively intended sphincter-preserving resection for UICC stage I through III rectal carcinoma between 01 Jan 2005 and 31 Dec 2007 with or without preoperative chemoradiotherapy (groups A and B, respectively) were included.
  • RESULTS: A total of 2,085 patients were included (group A, n = 676, group B, n = 1,409).
  • Significant differences were present between groups regarding age, sex, distance of the tumor from the anal verge, pT-stage, UICC stage, hepatic risk factors, and use of protective enterostomy by univariate analysis.
  • CONCLUSION: Neoadjuvant chemoradiotherapy for rectal carcinoma does not increase the risk for anastomotic leakage or postoperative bladder dysfunction after curatively intended sphincter-preserving rectal resection.
  • [MeSH-major] Anal Canal / surgery. Anastomotic Leak / etiology. Neoadjuvant Therapy. Postoperative Complications / etiology. Quality Assurance, Health Care. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy. Rectum / surgery. Urinary Bladder Diseases / etiology

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Langenbecks Arch Surg. 2007 Mar;392(2):179-88 [17279430.001]
  • [Cites] Dis Colon Rectum. 2008 Aug;51(8):1195-201 [18523823.001]
  • [Cites] Zentralbl Chir. 2006 Aug;131(4):275-84 [17004186.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):129-36 [19304407.001]
  • [Cites] Int J Colorectal Dis. 2008 Mar;23(3):257-64 [18071720.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):49-55 [2191763.001]
  • [Cites] Z Gastroenterol. 2008 Aug;46(8):799-840 [18759205.001]
  • [Cites] Chirurg. 2009 Apr;80(4):303-10 [19350307.001]
  • [Cites] Ann Surg. 2005 Oct;242(4):502-10; discussion 510-1 [16192810.001]
  • [Cites] Int MS J. 2009 Sep;16(3):90-7 [19878631.001]
  • [Cites] Dis Colon Rectum. 2005 Oct;48(10):1868-74 [16175323.001]
  • [Cites] Br J Surg. 2006 Dec;93(12):1519-25 [17054311.001]
  • [Cites] JAMA. 2000 Aug 23-30;284(8):1008-15 [10944647.001]
  • [Cites] Br J Surg. 2001 Nov;88(11):1501-5 [11683749.001]
  • [Cites] Chirurg. 2009 Apr;80(4):266-73 [19271158.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):817-25 [11821466.001]
  • [Cites] Langenbecks Arch Surg. 2007 Sep;392(5):525-33 [17394012.001]
  • [Cites] Chirurg. 2003 May;74(5):444-50; discussion 450-1 [12748793.001]
  • [Cites] Surg Oncol. 2007 Dec;16 Suppl 1:S83-9 [18042378.001]
  • [Cites] Int J Colorectal Dis. 2003 Nov;18(6):495-9 [14517686.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] Ann Surg Oncol. 2007 May;14(5):1744-51 [17334851.001]
  • [Cites] J Gastrointest Surg. 2009 Mar;13(3):521-5 [19011946.001]
  • [Cites] Eur J Surg Oncol. 2006 Dec;32(10):1201-8 [16872799.001]
  • [Cites] Acta Oncol. 2003;42(5-6):476-92 [14596508.001]
  • [Cites] Dis Colon Rectum. 2002 Jul;45(7):934-9 [12130883.001]
  • [Cites] Colorectal Dis. 2007 Nov;9(9):801-7 [17931170.001]
  • [Cites] Dis Colon Rectum. 2003 May;46(5):621-8 [12792438.001]
  • [Cites] Am Surg. 2004 Dec;70(12):1045-9 [15663042.001]
  • [Cites] Cancer. 1996 Sep 1;78(5):968-76 [8780533.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):6199-206 [16135487.001]
  • [Cites] Ann Surg Oncol. 1996 Sep;3(5):423-30 [8876883.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):6126-31 [16135478.001]
  • [Cites] Colorectal Dis. 2004 Nov;6(6):462-9 [15521937.001]
  • [Cites] Zentralbl Chir. 2009 Jun;134(3):242-8 [19536719.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1311-20 [12654443.001]
  • [Cites] Eur J Surg. 1996 May;162(5):397-402 [8781922.001]
  • [Cites] Lancet. 2001 Oct 20;358(9290):1291-304 [11684209.001]
  • (PMID = 20711786.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


22. Serra-Aracil X, Vallverdú H, Bombardó-Junca J, Pericay-Pijaume C, Urgellés-Bosch J, Navarro-Soto S: Long-term follow-up of local rectal cancer surgery by transanal endoscopic microsurgery. World J Surg; 2008 Jun;32(6):1162-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of local rectal cancer surgery by transanal endoscopic microsurgery.
  • BACKGROUND: In 1997 we launched a prospective program of transanal endoscopic microsurgery (TEM) for the treatment of rectal cancer.
  • (II) adenocarcinomas uT0 and uT1 with uN0;.
  • (III) adenocarcinomas uT2- uN0, low histological grade with intention to cure; and (IV) advanced stage adenocarcinomas with palliative care RESULTS: Transanal endoscopic microsurgery was performed in 218 patients: 122 adenomas, and 96 adenocarcinomas: group II-72, group III-19, and group IV-5.
  • Nine were lost to follow-up, and so 52 patients were studied: group II-38, group III-11, and group IV-3.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Female. Follow-Up Studies. Humans. Male. Microsurgery. Middle Aged. Prospective Studies. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):429-37 [15747069.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1182-92 [15793641.001]
  • [Cites] Am J Surg. 2000 Dec;180(6):402-5; discussion 405-6 [11182387.001]
  • [Cites] Hepatogastroenterology. 2005 Mar-Apr;52(62):460-3 [15816457.001]
  • [Cites] Dis Colon Rectum. 1983 Mar;26(3):149-51 [6825519.001]
  • [Cites] Dis Colon Rectum. 1995 Dec;38(12):1286-95 [7497841.001]
  • [Cites] Surg Laparosc Endosc. 1998 Aug;8(4):249-56 [9703594.001]
  • [Cites] Surg Endosc. 2003 Aug;17(8):1283-7 [12739119.001]
  • [Cites] Dis Colon Rectum. 1993 Jan;36(1):77-97 [8416784.001]
  • [Cites] Gut. 1977 Dec;18(12):1045-50 [606631.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):260-8 [15273550.001]
  • [Cites] Lancet. 1986 Jun 28;1(8496):1479-82 [2425199.001]
  • [Cites] Am J Surg. 1998 May;175(5):360-3 [9600277.001]
  • [Cites] Dis Colon Rectum. 2005 Apr;48(4):711-9; discussion 719-21 [15768186.001]
  • [Cites] Dis Colon Rectum. 1984 Feb;27(2):81-3 [6697834.001]
  • [Cites] Dis Colon Rectum. 1997 Apr;40(4):388-92 [9106685.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]
  • [Cites] Colorectal Dis. 2001 Mar;3(2):122-5 [12791005.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):522-29; discussion 529-30 [12368681.001]
  • [Cites] Dis Colon Rectum. 2000 Aug;43(8):1064-71; discussion 1071-4 [10950004.001]
  • [Cites] World J Surg. 2002 Sep;26(9):1170-4 [12209248.001]
  • [Cites] Colorectal Dis. 2004 Nov;6(6):432-7 [15521931.001]
  • [Cites] Ann Surg. 2000 Mar;231(3):345-51 [10714627.001]
  • [Cites] Ann Surg Oncol. 1999 Jul-Aug;6(5):433-41 [10458680.001]
  • [Cites] Dis Colon Rectum. 1994 Jan;37(1):52-7 [8287748.001]
  • [Cites] Am J Surg. 1992 Jan;163(1):63-9; discussion 69-70 [1733375.001]
  • (PMID = 18338206.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Chamlou R, Parc Y, Simon T, Bennis M, Dehni N, Parc R, Tiret E: Long-term results of intersphincteric resection for low rectal cancer. Ann Surg; 2007 Dec;246(6):916-21; discussion 921-2
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of intersphincteric resection for low rectal cancer.
  • INTRODUCTION: In the treatment of very low rectal cancer, a distal resection margin of more than 1 cm can be obtained by partial internal sphincteric resection, allowing a sphincter preserving surgery.
  • Thus, intersphincteric resection (ISR) has been proposed as an alternative to abdominoperineal resection for selected low rectal cancer.
  • Cancer-related survival and locoregional recurrence rates were calculated using the Kaplan-Meier method.
  • RESULTS: Ninety patients (59 males, 31 females) with a tumor at a median distance of 35 mm (range, 22-52) from the anal verge had an ISR.
  • Thirteen patients (14.4%) died of cancer recurrence.
  • In univariate analysis, overall survival was significantly influenced by pTNM stage and T stage (pT 1-2 vs. 3-4: P = 0.008 and stage I-II vs. III-IV: P = 0.03).
  • After adjustment for age, gender, tumor level, and pTNM stage, preoperative radiotherapy was the only factor associated with a risk of fecal incontinence [OR (IC 95%) = 3.1 (1.0-9.0), P = 0.04].
  • [MeSH-major] Adenocarcinoma / epidemiology. Anal Canal / surgery. Colectomy / methods. Rectal Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043092.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Prete F, Prete FP, Nitti P, De Luca R, Vincenti L: [Evolution of surgery for cancer of the anorectal junction]. Chir Ital; 2007 Nov-Dec;59(6):763-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evolution of surgery for cancer of the anorectal junction].
  • [Transliterated title] Evoluzione chirurgica per i tumori del giunto ano-rettale.
  • Certain aspects of the epidemiology, classification and therapy of adenocarcinoma of the anorectal junction (< 5 cm from the anal verge) are not well standardised to date.
  • Intersphincteric resections were performed in 51 males and 33 females, mean age 62, with the following clinical stages: 28 stage 1, 55 stages II and III, 1 stage IV; radiotherapy was administered preoperatively to 27 patients and postoperatively to 18.
  • Assessment of anal sphincter function recovery one year after restoration of bowel continuity showed good continence in 76% of the patients; 2 patients have a permanent ostomy.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18360980.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


25. Akasu T, Takawa M, Yamamoto S, Ishiguro S, Yamaguchi T, Fujita S, Moriya Y, Nakanishi Y: Intersphincteric resection for very low rectal adenocarcinoma: univariate and multivariate analyses of risk factors for recurrence. Ann Surg Oncol; 2008 Oct;15(10):2668-76

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: One hundred twenty consecutive patients with T1-T3 rectal cancers located 1-5 (median 3) cm from the anal verge underwent ISR.
  • RESULTS: Fifty patients had disease categorized as stage I, 21 as stage II, 46 as stage III, and 3 as stage IV on the basis of International Union Against Cancer tumor, node, metastasis staging system.
  • Univariate analysis of the risk factors for local recurrence revealed pathologic T, pathologic stage, focal dedifferentiation, microscopic resection margins, and preoperative serum CA 19-9 level to be statistically significant.
  • Univariate analysis of the risk factors for distant recurrence indicated tumor location, combined resection, tumor annularity, pathologic N, lateral pelvic lymph node metastasis, pathologic stage, histologic grade, lymphovascular invasion, perineural invasion, and adjuvant chemotherapy to be significant.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Neoplasm Recurrence, Local / diagnosis. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18618181.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-19-9 Antigen
  •  go-up   go-down


26. Yoo JH, Hasegawa H, Ishii Y, Nishibori H, Watanabe M, Kitajima M: Long-term outcome of per anum intersphincteric rectal dissection with direct coloanal anastomosis for lower rectal cancer. Colorectal Dis; 2005 Sep;7(5):434-40
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of per anum intersphincteric rectal dissection with direct coloanal anastomosis for lower rectal cancer.
  • With direct coloanal anastomosis for cases of lower rectal cancer in which the distal surgical margin is difficult to secure by the double stapling technique.
  • Of these, two patients (one stage 0 and one stage IV) were excluded from the analysis of oncological outcome.
  • There was an association between distant metastasis and TNM or pT stage.
  • The overall survival rates for stage I, II and III were 85%, 80% and 89%, respectively.
  • CONCLUSION: The surgical indications of this operation should be limited to patients with T1 rectal cancer or tumours less than 3 cm.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Fecal Incontinence / epidemiology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Proctocolectomy, Restorative. Rectum / surgery. Surveys and Questionnaires. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16108877.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


27. Choi GS, Park IJ, Kang BM, Lim KH, Jun SH: A novel approach of robotic-assisted anterior resection with transanal or transvaginal retrieval of the specimen for colorectal cancer. Surg Endosc; 2009 Dec;23(12):2831-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel approach of robotic-assisted anterior resection with transanal or transvaginal retrieval of the specimen for colorectal cancer.
  • The tumor stage was I in four, II in two, and III in seven patients.
  • CONCLUSION: Robotic-assisted laparoscopic methods were safe for AR in patients with colorectal cancer.
  • [MeSH-minor] Adult. Aged. Anal Canal. Female. Humans. Length of Stay. Male. Middle Aged. Vagina

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2001 Nov;25(11):1408-11 [11760744.001]
  • [Cites] Surg Endosc. 2002 Sep;16(9):1267-70 [12235507.001]
  • [Cites] Int J Gynaecol Obstet. 2005 Oct;91(1):27-31 [16051243.001]
  • [Cites] Fertil Steril. 2000 May;73(5):1040-2 [10785235.001]
  • [Cites] J Am Assoc Gynecol Laparosc. 2004 Feb;11(1):42-6 [15104829.001]
  • [Cites] Arch Surg. 2003 Jul;138(7):777-84 [12860761.001]
  • [Cites] Ann Surg Oncol. 2007 Nov;14(11):3168-73 [17763911.001]
  • [Cites] Dis Colon Rectum. 2002 Dec;45(12):1689-94; discussion 1695-6 [12473897.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2002 Feb;12(1):1-5 [12008756.001]
  • [Cites] Surg Endosc. 2003 Oct;17(10):1521-4 [12915974.001]
  • [Cites] Int J Colorectal Dis. 2008 Jul;23(7):703-7 [18379795.001]
  • [Cites] Surg Endosc. 2001 Sep;15(9):918-23 [11605106.001]
  • [Cites] Surg Endosc. 2006 Nov;20(11):1713-8 [17008953.001]
  • [Cites] Fertil Steril. 1996 Jan;65(1):193-7 [8557141.001]
  • [Cites] Dis Colon Rectum. 2004 Dec;47(12):2162-8 [15657669.001]
  • [Cites] J Urol. 2001 Jun;165(6 Pt 1):1964-6 [11371890.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2002 Feb;12(1):41-5 [12008761.001]
  • [Cites] Surgery. 2002 Jan;131(1 Suppl):S330-3 [11821833.001]
  • [Cites] Surg Endosc. 2002 Oct;16(10):1389-402 [12140630.001]
  • [Cites] Surg Endosc. 2008 Mar;22(3):792-7 [18027033.001]
  • [Cites] Surg Endosc. 2006 Oct;20(10):1521-5 [16897284.001]
  • [Cites] Surg Endosc. 2002 Dec;16(12):1691-6 [12140631.001]
  • [Cites] Heart Surg Forum. 2001;4(4):307-10 [11827857.001]
  • (PMID = 19440794.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Video-Audio Media
  • [Publication-country] Germany
  •  go-up   go-down


28. Pocard M, Sabourin JC: [Sentinel lymph node biopsy in gastro-intestinal surgery: facts and future implications]. J Chir (Paris); 2008 Dec;145 Spec no. 4:12S17-12S20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In theory, the concept of sentinel lymph node (SLN) biopsy can be applied to cancer surgery for all solid cancers.
  • Yet sentinel lymph node biopsy has not become a standard part of gastrointestinal cancer surgery.
  • It has been of value in the assessment of small early-stage gastric cancers, but has only achieved widespread practice in Japan.
  • Studies of SLN biopsy in colon cancer have not shown it to be a reliable predictor of N+ status and therefore don't permit the omission of lymph node dissection in selected cases.
  • SLN biopsy may have prognostic usefulness by demonstrating micrometastases; careful serial sectioning focussed on the SLN may detect nests of metastatic cells on HE staining, thereby converting a tumor from Stage I (TxN0M0) to Stage II (TxN1M0).
  • For cancers of the anal canal, SLN biopsy of inguinal nodes has been tested as a means of establishing the indications for inguinal lymph node dissection.
  • [MeSH-minor] Anus Neoplasms / surgery. Colonic Neoplasms / surgery. Digestive System Surgical Procedures. Humans. Neoplasm Staging. Prognosis. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19194353.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 99
  •  go-up   go-down


29. Pocard M, Sabourin JC: [Not Available]. J Chir (Paris); 2008 Dec;145S4:12S17-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sabourin In theory, the concept of sentinel lymph node (SLN) biopsy can be applied to cancer surgery for all solid cancers.
  • Yet sentinel lymph node biopsy has not become a standard part of gastrointestinal cancer surgery.
  • It has been of value in the assessment of small early-stage gastric cancers, but has only achieved widespread practice in Japan.
  • Studies of SLN biopsy in colon cancer have not shown it to be a reliable predictor of N+ status and therefore don't permit the omission of lymph node dissection in selected cases.
  • SLN biopsy may have prognostic usefulness by demonstrating micrometastases; careful serial sectioning focussed on the SLN may detect nests of metastatic cells on HE staining, thereby converting a tumor from Stage I (TxN0M0) to Stage II (TxN1M0).
  • For cancers of the anal canal, SLN biopsy of inguinal nodes has been tested as a means of establishing the indications for inguinal lymph node dissection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2008 Elsevier Masson SAS. All rights reserved.
  • (PMID = 22793980.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


30. Pocard M, Sabourin JC: [Not Available]. J Chir (Paris); 2008 Dec;145(6S1):12S17-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sabourin In theory, the concept of sentinel lymph node (SLN) biopsy can be applied to cancer surgery for all solid cancers.
  • Yet sentinel lymph node biopsy has not become a standard part of gastrointestinal cancer surgery.
  • It has been of value in the assessment of small early-stage gastric cancers, but has only achieved widespread practice in Japan.
  • Studies of SLN biopsy in colon cancer have not shown it to be a reliable predictor of N+ status and therefore don't permit the omission of lymph node dissection in selected cases.
  • SLN biopsy may have prognostic usefulness by demonstrating micrometastases; careful serial sectioning focussed on the SLN may detect nests of metastatic cells on HE staining, thereby converting a tumor from Stage I (TxN0M0) to Stage II (TxN1M0).
  • For cancers of the anal canal, SLN biopsy of inguinal nodes has been tested as a means of establishing the indications for inguinal lymph node dissection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2008 Elsevier Masson SAS. All rights reserved.
  • (PMID = 22794067.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down






Advertisement